Immetas Therapeutics is a New Jersey biotech building drugs that target the chronic, low-grade inflammation that drives aging and age-related disease - what scientists call 'inflammaging.' Founded in 2018 by drug-development veteran J. Gene Wang and Harvard aging researcher David Sinclair, the company designs bispecific antibodies and other biologics to reprogram the innate immune system, aiming to treat age-related cancers and inflammatory and autoimmune disease. It raised an $11M Series A from Morningside Ventures in 2020 and partners with GC Biopharma on mRNA therapeutics.
J. Gene Wang is a physician-scientist and the founder and CEO of Immetas Therapeutics, a biotech he co-founded in 2018 with Harvard's David Sinclair to attack the chronic, low-grade inflammation that drives aging and age-related cancers. Trained with an M.D. from Peking University and a Ph.D. in immunobiology from Yale, Wang spent roughly two decades inside Merck, Abbott, GSK, and Novartis, where he helped move blockbuster drugs like Humira, Gardasil, Zolinza, and Varubi from lab bench to patients. At Immetas he is engineering bispecific antibodies designed to retune inflammation inside the tumor microenvironment and break resistance to checkpoint immunotherapy, backed by an $11M Series A from Morningside Ventures.